Immuron Limited

IMC

AU000000IMC7

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 06:48:52 16/07/2024 BST			5-day change	1st Jan Change
0.1 ^AUD	+2.04%		+20.48%	+29.87%

07-15	Immuron Limited Reports Unaudited Sales Results for the Fiscal Fourth Quarter and Full Year Ended June 2024	CI
07-15	Immuron Posts 253% Jump in Travelan Sales in Fiscal Q4; Shares Rise 10%	MT

Immune Biologics Pty Ltd cancelled the acquisition of IMM-124E from Immuron Limited.

January 06, 2016 at 04:00 am

Immune Biologics Pty Ltd agreed to acquire IMM-124E from Immuron Limited (ASX:IMC) on January 6, 2015. The deal is subject to a successful outcome of the clinical trials designed to test the efficacy of IMM-124E to be undertaken by Immune Biologics.

Immune Biologics Pty Ltd cancelled the acquisition of IMM-124E from Immuron Limited (ASX:IMC) on January 6, 2016.

Latest news about Immuron Limited

Immuron Limited Reports Unaudited Sales Results for the Fiscal Fourth Quarter and Full Year Ended June 2024	07-15	CI
Immuron Posts 253% Jump in Travelan Sales in Fiscal Q4; Shares Rise 10%	07-15	MT
Immuron Files for Mixed-Shelf Offering; Plans to Raise $2M Through At-The-Market Equity Sale	07-03	MT
Immuron Requests Meeting With FDA for Potential Colon Infection Therapy	07-02	MT
Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing	07-02	CI
Immuron Files Pre-Investigational New Drug Application with FDA for IMM-529	07-02	MT
Immuron Limited Appoints Jeannette Joughin as Director	06-05	CI
Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director	05-31	CI
Immuron Limited Announces Stephen Anastasiou Has Resigns as Non-Executive Director	05-02	CI
Immuron Limited Provides Sales Results for the Quarter and Year to Date Ended March 2024	04-10	CI
Immuron's Global Sales Climb 51% in March Quarter; Shares Surge 18%	04-10	MT
Sector Update: Health Care Stocks Gain Late Afternoon	03-07	MT
Sector Update: Health Care	03-07	MT
Top Midday Gainers	03-07	MT
Top Premarket Gainers	03-07	MT
Immuron Moving Anti-Diarrhea Drug to Phase Three Trials	03-07	MT
Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US	03-07	CI
Immuron Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Immuron Limited Reports Unaudited Net Sales Results for the Year to Date Ended January 2024	02-13	CI
Immuron's Travelan Immune Supplement Registers AU$2.7 Million Sales in YTD January	02-13	MT
Immuron Limited Reports Sales Results for First Half 2024	01-16	CI
Immuron Posts Record Travelan Sales in Fiscal H1	01-16	MT
Immuron Limited Clinical Trials Update	12-22	CI
Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study	12-04	CI
Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences	18/10/23	CI

Chart Immuron Limited

Duration

Period

More charts

Company Profile

Immuron Limited is an Australia-based biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases. It operates through two segments: Research and development (R&D), and Hyperimmune products. The R&D segment is focused on R&D projects performed in Australia and the United States. Hyperimmune products segment is engaged in Travelan and Protectyn activities which occur predominantly in Australia, the United States and Canada. Its flagship products consist of Travelan and Protectyn. Travelan is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelerâs diarrhea and is sold in pharmacies throughout Australia. Protectyn is sold online and in health practitioner clinics and is marketed as an immune supplement to help maintain a healthy digestive function and liver. Its clinical programs include Travelan (IMM-124E), IMM-529, and CampETEC.

Sector

Pharmaceuticals

Calendar

29/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Biopharmaceuticals

	1st Jan change	Capi.
IMMURON LIMITED	+29.87%	15.14M
CSL LIMITED	+7.40%	101B
SAMSUNG BIOLOGICS CO.,LTD.	+7.76%	42.18B
BIOGEN INC.	-14.37%	32.26B
UCB	+80.54%	29.79B
BIOMARIN PHARMACEUTICAL INC.	-12.27%	16.06B
INCYTE CORPORATION	+2.33%	14.45B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-8.56%	12.01B
ALTEOGEN INC.	+182.74%	10.71B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.89B